Dark

Check out our API

SNSS
Sunesis Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive

Feb 25, 2021

13.50USD+153.759%(+8.18)622,246

Pre-market

0.00USD-100.000%(-5.32)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Feb 24, 2021

04:06PM EST Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals PR Newswire

12:12PM EST Mid-Day Market Update: US Stocks Turn Higher; Systemax Shares Fall Following Q4 Earnings Benzinga

10:14AM EST Mid-Morning Market Update: Markets Open Lower; Lowe's Beats Q4 Estimates Benzinga

Feb 23, 2021

02:33PM EST Mid-Afternoon Market Update: Dow Falls 60 Points; Churchill Capital IV Shares Plunge Benzinga

12:30PM EST Mid-Day Market Update: Nasdaq Drops 250 Points; Frank's International Shares Jump Following Q4 Earnings Benzinga

11:08AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2021 Benzinga

11:07AM EST Mid-Morning Market Update: Markets Open Lower; Home Depot Tops Q4 Views Benzinga

07:38AM EST Sunesis Pharmaceuticals Shares Up 40%; Co Earlier Announced Vote Approving Reverse Stock Split Within Range Between 3-for-1 And 6-For-1; Approved Issuance Of Shares Of Co's Stock Pursuant To Merger Benzinga

06:00AM EST Oppenheimer Upgrades Sunesis Pharmaceuticals to Outperform, Announces $12 Price Target Benzinga

Feb 16, 2021

12:56PM EST Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime Benzinga

08:05AM EST Sunesis Merger Partner Viracta Therapeutics Announces Notice Of Allowance For US Patent Application Covering Use Of Its Combination Product Candidate For Treatment Of Epstein-Barr Virus-Associated Lymphoma Benzinga

08:01AM EST Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma PR Newswire

Feb 11, 2021

04:06PM EST Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences PR Newswire

Jan 7, 2021

05:58PM EST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of GlobeNewswire Inc

Jan 5, 2021

11:28AM EST ALERT: Halper Sadeh LLP Investigates TDY, TCP, BEAT, HCAP, SNSS; Shareholders PR Newswire

Jan 4, 2021

12:41PM EST Sunesis Pharma 13G From Laurence Lytton Shows 8.8% Stake In Co. Benzinga

Dec 30, 2020

08:49PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds HLIX, XLNX, SNSS, and AKER Shareholders PR Newswire

11:55AM EST SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers PR Newswire

Dec 29, 2020

07:00PM EST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of GlobeNewswire Inc

05:56PM EST SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS Business Wire

Dec 22, 2020

06:36AM EST Sunesis Pharmaceuticals Says On Dec 16, Dayton Misfeldt Provided Notice Of Resignation As Co.'s Interim CEO, Effective Dec 31; Board Appointed Parvinder S. Hyare As Interim CEO, Effective Jan 1, 2021 Benzinga

Dec 19, 2020

04:55PM EST SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following PR Newswire

Dec 18, 2020

10:16PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds NGA, FIII, and SNSS Shareholders About PR Newswire

Dec 17, 2020

02:49PM EST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of GlobeNewswire Inc

Dec 12, 2020

08:52AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Dec 11, 2020

09:40PM EST Pfizer, BioNTech's COVID-19 Vaccine Receives FDA Emergency Use Authorization RTTNews

08:55PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds CLCT, SNSS, WTRE, and STPK Shareholders PR Newswire

Dec 7, 2020

08:33AM EST Viracta Therapeutics Reports Presentation Of Updated Phase 2 Data At ASH 2020 RTTNews

08:31AM EST Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 PR Newswire

06:59AM EST UPDATE: Viracta Therapeutics Announces 'Recent End of Phase 2 Meeting supports advancement into single-arm registration trial and Registration trial for the treatment of relapsed/refractory EBV+ lymphomas to begin in 1H2021' Benzinga

06:59AM EST Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA Benzinga

06:59AM EST UPDATE: Viracta Therapeutics Announces 'Promising data show complete responses observed across multiple subtypes of Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL' Benzinga

Dec 4, 2020

09:14PM EST SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PR Newswire

Dec 3, 2020

05:17PM EST SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS Business Wire

Dec 2, 2020

08:00AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: GlobeNewswire Inc

Dec 1, 2020

11:41AM EST Moore Kuehn Encourages HDS, GV, CLCT and SNSS Investors to Contact Law Firm PR Newswire

09:36AM EST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation GlobeNewswire Inc

01:13AM EST Merger Investigations; Investors are Encouraged to Contact the Firm - CLCT, INFO, SNSS, RESI, CIT PR Newswire

Nov 30, 2020

08:34PM EST SHAREHOLDER ALERT: WeissLaw LLP Investigates Sunesis Pharmaceuticals, Inc. PR Newswire

04:59PM EST Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by an investor group led by Viracta Therapeutics, Inc. GlobeNewswire Inc

11:43AM EST Sunesis Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Sunesis Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - SNSS Business Wire

07:43AM EST Sunesis And Viracta Therapeutics Enter Definitive Merger Agreement RTTNews

07:31AM EST Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement; Viracta Stockholders Are Expected To Own Approximately 86% And Sunesis Stockholders Will Own Approximately 14% Of The Combined Company Benzinga

07:30AM EST Merger to create Nasdaq-listed company focused on developing Viractas precision oncology pipeline targeting virus-associated malignancies GlobeNewswire Inc

Nov 16, 2020

04:16PM EST Sunesis Pharmaceuticals Q3 EPS $(0.29) Beats $(0.34) Estimate Benzinga

04:05PM EST Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial GlobeNewswire Inc

04:26AM EST Earnings Scheduled For November 16, 2020 Benzinga

Nov 9, 2020

07:00AM EST Sunesis Pharmaceuticals, Inc.(Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2020. GlobeNewswire Inc

Oct 30, 2020

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 12, 2020

07:00AM EDT Sunesis Pharmaceuticals, Inc.(Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format. GlobeNewswire Inc

Sep 3, 2020

09:55AM EDT Return On Capital Employed Overview: Sunesis Pharmaceuticals Benzinga

07:00AM EDT Sunesis Pharmaceuticals, Inc.(Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences. GlobeNewswire Inc

Sep 2, 2020

12:57PM EDT Sunesis Pharma Reports 1-For-10 Reverse Stock Split Effective After Close Today, Sept. 2 Benzinga

12:50PM EDT Sunesis Pharmaceuticals Announces 1-For-10 Reverse Stock Split Effective 5 p.m. EDT Today Benzinga

12:49PM EDT Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split GlobeNewswire Inc

Aug 11, 2020

06:18PM EDT Recap: Sunesis Pharmaceuticals Q2 Earnings Benzinga

04:26PM EDT Sunesis Pharmaceuticals Q2 EPS $(0.06), Inline Benzinga

04:05PM EDT Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 11, 2020 Benzinga

Aug 10, 2020

11:12AM EDT Earnings Preview for Sunesis Pharmaceuticals Benzinga

Aug 7, 2020

02:55PM EDT Sunesis Pharma 13G Filing From Ayrton Capital Shows 6.65% Stake In Co. Benzinga

Aug 4, 2020

07:00AM EDT Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc

Jul 29, 2020

02:38PM EDT Mid-Afternoon Market Update: Dow Climbs 140 Points; Civeo Shares Jump Following Upbeat Q2 Results Benzinga

12:00PM EDT Mid-Day Market Update: Nasdaq Surges Over 100 Points; Eastman Kodak Shares Spike Higher Benzinga

09:11AM EDT Sunesis Announces Pricing Of $12M Offering At $0.23/Share Benzinga

09:05AM EDT Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of common stock is $0.23. GlobeNewswire Inc

Jul 28, 2020

04:08PM EDT Sunesis Reports Common Stock Offering, No Size Disclosed Benzinga

04:08PM EDT Sunesis Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Share